Compare Coursera Inc (COUR) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Davita Inc — how do they compare? Coursera Inc trades at $5.28 (market cap $1.35B), while Davita Inc trades at $175.04 (market cap $11.29B). The key difference: Davita Inc is far larger — about 8.4× Coursera Inc's market cap, and Davita Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coursera Inc for 47 Days and Davita Inc for 113 Days on average.
| COUR | DVA | |
|---|---|---|
Market Cap | $1.35B | $11.29B |
Volume | 5,442,629 | 582,204 |
Sector | Consumer Staples | Health |
52-Week High | $10.73 | $240.96 |
52-Week Low | $4.64 | $103.87 |
Typical Hold Time | 47 Days | 113 Days |
Enterprise Value | $606.18M | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.11, down 0.2% on the day, with a bearish technical signal and neutral oscillators. Revenue has grown from $524M in 2022 to $757.5M in 2025, but the company remains unprofitable with a net loss of $51M in 2025. Recent news highlights AI platform developments and significant institutional buying interest.
The stock offers potential upside to the $7.40 analyst consensus target but faces risks from persistent losses and competitive pressures. Positive cash flow and subscriber growth are key strengths, yet profitability challenges and integration costs from recent acquisitions present headwinds for near-term performance.
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
